Avadel Pharmaceuticals (AVDL) EBT: 2009-2021
Historic EBT for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBT fell 346.73% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 2379.58%. This contributed to the annual value of -$85.5 million for FY2021, which is 364.17% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported EBT of -$23.1 million as of Q4 2021, which was up 9.85% from -$25.7 million recorded in Q3 2021.
- In the past 5 years, Avadel Pharmaceuticals' EBT ranged from a high of $36.3 million in Q2 2017 and a low of -$78.4 million during Q4 2018.
- Moreover, its 3-year median value for EBT was -$14.7 million (2019), whereas its average is -$13.8 million.
- In the last 5 years, Avadel Pharmaceuticals' EBT spiked by 2,647.13% in 2017 and then tumbled by 1,278.68% in 2018.
- Over the past 5 years, Avadel Pharmaceuticals' EBT (Quarterly) stood at -$5.7 million in 2017, then plummeted by 1,278.68% to -$78.4 million in 2018, then skyrocketed by 30.43% to -$54.5 million in 2019, then surged by 90.50% to -$5.2 million in 2020, then tumbled by 346.73% to -$23.1 million in 2021.
- Its EBT was -$23.1 million in Q4 2021, compared to -$25.7 million in Q3 2021 and -$23.3 million in Q2 2021.